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The reversible combination of thyroxine with
certain of the plasma proteins clearly provides an
efficient transport mechanism enabling microgram
quantities of the hormone to be carried to tissue
sites with minimal losses via glomerular filtration
and other nonselective excretory pathways. The
demonstration of thyroxine-binding proteins in
other extracellular fluids (1) and within cells (2)
suggests a means by which thyroxine may be se-
lectively distributed to tissues according to their
individual needs.
The role, if any, of the plasma thyroxine-binding
proteins in various thyroid disorders is not clear.
In vitro studies of the protein-thyroxine complex
involve alterations of pH, Pco2, temperature and
other aspects of the biochemical environment and
may not give an accurate index of in vivo rela-
tionships. Furthermore, such studies neglect in-
teractions of plasma thyroxine-binding proteins
and extravascular thyroxine-binding proteins.
It seemed reasonable to suppose that the rate
of disappearance of I131-labeled L-thyroxine (T4*)
from the intravascular compartment during an
acute experiment might yield information about
the rate at which equilibrium between intra- and
extravascular compartments was approached.
The rate of disappearance should reflect the ability
of the serum proteins to bind thyroxine and re-
tain it within the vascular compartment in the face
of all ambient forces favoring its removal. Con-
ventional studies of labeled thyroxine survival
(measured in days) are presumed to measure pri-
marily the rate of thyroxine disposal after equili-
bration between labeled and stable thyroxine has
been attained throughout the body. In preliminary
studies, attempts were made to measure the rate
* This investigation was supported in part by Public
Health Service Grants A-1200 and 2A-5023, National
Institute of Arthritis and Metabolic Diseases, Bethesda,
Md.
of disappearance of T4* from the circulation of
isolated extremities but technical problems pre-
cluded accurate measurement. A whole-body
technic was therefore employed and found to be
satisfactory.
The method consisted in determining the rate
of disappearance of I131-L-thyroxine from the in-
travascular compartment of human subjects dur-
ing a 30-minute period after allowing 20 minutes
from time of intravenous injection for thorough
intravascular mixing. The unsteady state pre-
vailing shortly after the injection of T4* was de-
liberately selected for the period of study because
the rate of loss of T4* from the circulation is maxi-
mal at this time and the apparent volume of dis-
tribution is rapidly expanding. The rate of disap-
pearance was calculated and was shown to be
reproducible.
Experimental results indicate: a) a profound
influence of the liver on the acute disappearance
rate of T4*, indicated by a markedly prolonged
intravascular retention of thyroxine in subjects
with hepatic disease; b) rapid disappearance of
T4* in patients with diffuse toxic goiter (Graves'
disease), but no significant change from normal
in subjects fed large doses of desiccated thyroid,
and slight prolongation of disappearance rate in
subjects with toxic nodular goiter; and c) marked
prolongation of disappearance rate in subjects
with spontaneous myxedema, but no similar pro-
longation in subjects with Graves' disease who de-
veloped myxedema after treatment of hyperthy-
roidism.
MATERIAL AND METHODS
Each subject was evaluated by one or more of the
authors and a clinical impression of the state of thyroidal
function was made without reference to laboratory stud-
ies. Impressions were confirmed by serum protein-bound
iodine (PBI) determinations and, in some instances, by
measuring the thyroidal 24-hour uptake of P131. The
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control group consisted of 15 euthyroid subjects ranging
from 13 to 76 years of age. None had clinical evidence of
hepatic or renal disease, but some suffered from a variety
of other nonfebrile illnesses, e.g., generalized arterio-
sclerosis, carcinoma of the lung, mild malnutrition, com-
pensated heart disease, and so forth.
The study groups consisted of 9 euthyroid subjects with
liver disease, 7 subjects with toxic nodular goiter, 9 with
Graves' disease and thyrotoxicosis, 4 subjects with Graves'
disease who had become euthyroid after treatment (one
of these receiving 3 grains of desiccated thyroid daily
because of moderate exophthalmos), 5 subj ects with
Graves' disease who were myxedematous as a result of
treatment and 7 subjects with spontaneous primary myx-
edema. In addition, 10 subjects whose ranges of acute
thyroxine disappearance rate approximated the ranges
observed among the various groups were subjected to a
second study 2 to 4 days after the initial measurement
to estimate reproducibility of the method.
Subjects were brought to the radioisotope laboratory
in the early afternoon without special preparation. A
no. 18 needle was inserted and secured in an antecubital
vein and connected to one limb of a Radicoil (Abbott)
resting in a shielded well-type scintillation counter.
The other limb of the Radicoil was connected via a
three-way stopcock to a 20 ml syringe and a solution of
50 mg aqueous heparin in 500 ml of isotonic saline.
Blood was withdrawn through the Radicoil to the 10
ml mark of the syringe, counted for 1 minute, and re-
injected into the subject. This step was repeated one or
more times, depending on background radioactivity. At
time zero, a 20 to 30 ,tc dose of T4* of high specific ac-
tivity (Abbott) was injected into a vein in the opposite
arm. The T4* was used within 7 days of delivery; it
was not rechromatographed before use since prior stud-
ies indicated that free I13. had little influence on the func-
tion being measured. The three-way stopcock was ad-
justed to permit a slow drip of the heparin solution to
prevent clotting in the indwelling needle. At 5-minute
intervals, blood was drawn into the Radicoil, counted
for 1 minute and reinjected. Care was taken to draw
the blood slowly (20 seconds) to the 10 ml mark of the
syringe to prevent variations in mixing and dilution.
Counting at 5-minute intervals was continued for 50 to 60
minutes after injection of the T4*. There was no sig-
nificant adherence of thyroxine to the plastic Radicoil in
the presence of plasma proteins.
RESULTS
When the curve of thyroxine disappearance is
derived on semilog paper by plotting the net
counts per minute (log scale) against time (linear
scale), three distinct components of the curve are
apparent. The first component. with most rap-
idly declining concentration of To*, extends from
0 to 10 or 20 minutes after injection and primarily
represents mixing and dilution of the T4* within
the vascular compartment. In normal subjects
this brief, initial phase requires less than 10 min-
utes; however, when circulation is slowed, as in
myexedma, it may extend to 20 minutes. Even in
this brief period of mixing, simultaneous egress
of T4* from the circulation will occur, but it is
not possible to separate that decline in radioac-
tivity due to mixing from that due to extravascu-
lar movement. The moment when mixing is com-
plete and when the decrements of T4* largely
represent egress from the circulation, cannot be
ascertained.
The second component is curvilinear and ex-
tends for 1 or 2 days. It primarily represents mix-
ing of T4* throughout the body with establishment
of an equilibrium between labeled and stable thy-
roxine. The curvilinear regression clearly repre-
sents the simiultaneous operation of a number of
processes: a) egress from the circulation-the
rate of fall in plasma radioactivity by this function
will be greatest when intravascular concentration
of T4* is highest, i.e., the early part of the curve;
b) re-entry of T4* into the circulation from the
extravascular compartment-as extravascular con-
centrations of T4* slowly increase, the contribution
to plasma radioactivity increases; c) superimposed
is the third component of the curve-the disposal
of thyroxine from the body.
TIME (MINUTES)
FIG. 1. THREE ILLUSTRATIVE CURVES PLOTTED ON SEMI-
LOG PAPER SHOWING THE REGRESSION OF NET COUNTS PER
MINUTE ON TIME AFTER INTRAVENOUS INJECTION OF I"-
L-THYROXINE. TTIE HALF-TIME VALUE IS DERIVED FRO-M
CALCULATION OF THE SLOPE OF THAT SEGMENT OF THE
CURVE BETWEEN 20 AND 50 MINUTES.
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TABLE I
Replicate determinations of acute thyroxine disappearance*
Acute thyroxine
disappearance rate
Half-time
First Second
Subject study study Difference Difference
min min min %
A.K. 57.8 56.5 - 1.3 - 2.30
R.B. 43.9 44.1 + 0.2 + 0.46
B.P. 71.8 78.8 + 7.0 + 9.75
E.K. 96.5 88.3 - 8.2 - 8.50
F.H. 114.0 109.1 - 4.9 - 4.30
C.B. 65.4 68.1 + 2.7 + 4.13
H.S. 59.1 54.5 - 4.6 - 7.78
F.T. 123.4 103.8 -19.6 -15.88
L.J. 99.7 84.6 -15.1 -15.14
L.B. 55.6 63.5 + 7.9 +14.21
Mean 78.7 75.1 - 3.6 - 2.5
SDt : 8.9 i 9.9
* Second studies were performed 2 to 4 days after initial
studies.
t Standard deviation.
The third component is practically linear and
can be measured after equilibration is established
(3). The normal half-time of thyroxine "sur-
vival" or disposal is about 6 days. Since the
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half-time is 3 or more days even in hyperthyroid
states, the slope of this linear component, when
considered over a 30-minute period, is almost im-
perceptible and could influence calculated results
very little.
Thus, while all of the above simultaneously oc-
curring processes can not be separated, to obtain
some measure or approximation of the net effect
of forces favoring retention and removal of intra-
vascularly injected (initially unbound) T4*, at-
tention must be directed to the interval when T44
concentrations are highest and decreasing most
rapidly. While the mixing phase is rapid in nor-
mals, it may require as long as 20 minutes in some
patients with myxedema. Therefore, so as to be
able to compare different groups in a similar man-
ner and since the "rate" was obtained by calcula-
tion rather than a visual fit, the regression from
20 to 50 minutes was chosen for analysis (Figure
1 and Table II). In this interval mixing should
have been completed, re-entry of T4* from ex-
travascular spaces should be small although per-
haps not insignificant in all circumstances, and
* Euthiroid
X On thyroid 209r./day
X Toxic nodular goiter
Spontaneous myxedemr.
A Graves' - hyperthyroid
o - euthtyroid
Ad Ad - hypothyroid
A Liver disease
* X
x X X zK~~~~~~~~~
X
1* X
0 4 8 12 16 20 24 28
PBI
FIG. 2. THE RELATIONSHIP BETWEEN PBI, REFLECTING LEVELS OF THYROIDAL
ACTIVITY, AND THE ACUTE THYROXINE DISAPPEARANCE RATE.
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TABLE II
Experimental results for control subjects and study groups
Thyroidal Acute thyroxine
24 hr. I'M3 disappearance rateGroup Subject Age Sex Race PBI uptake Half-time
Healthy,
euthyroid
M.P.
E.R.
A.D.
A.Da.
D.D.
D.E.
D.Z.
I.J.
L.C.
M.S.
P.W.
W.S.
R.Q.
C.A.
G.K.
yrs
34
29
44
75
28
13
48
42
47
76
53
36
25
29
42
F
F
M
M
M
M
F
F
M
M
M
M
M
M
M
N.
Cau.
Cau.
Cau.
Cau.
Cau.
Cau.
N.,
Cau.
Cau.
Cau.
N.
Cau.
N.
Cau.
Isg%
5.2
3.8
3.9
5.8
3.3
7.5
5.8
4.5
3.5
5.9
4.4
5.8
5.4
6.7
6.8
21.9
min
71.8
63.1
76.6
77.4
75.8
82.7
78.6
77.4
72.0
73.2
61.6
66.2
69.4
86.5
77.2
10.6
18.5
10.7
21.6
19.5
A.K.
E.A.
M.H.
L.K.
I.A.
A.S.
E.K.
M.R.
S.B.
M.G.
S.T.
M.S.
D.A.
E.H.
K.M.
M.P.
R.B. 27
S.T. 54
V.H. 28
K.S. 48
S.N. 19
M.R. 34
B.W. 30
D.A.* 32
E.C. 56
50 F Cau.
77 F Cau.
70 F Cau.
68 F Cau.
76 F Cau.
65 F Cau.
49 F Cau.
21 F N.
67 M Cau.
39 F N.
54 F Cau.
26 F Cau.
32 F Cau.
54 M Cau.
47 F Cau.
30 F Cau.
M Cau.
F Cau.
F Cau.
F Cau.
F Cau.
F Cau.
F Cau.
F Cau.
F Cau.
5.8
7.4
7.7
12.0
7.9
6.8
16.6
20.0
8.5
15.3
15.2
13.6
25.3
20.2
7.0
5.6
9.9
5.8
1.5
1.0
2.1
1.5
1.6
56.2
42.1
54.4
44.2
48.5
32.4
49.0
36.6
71.5
67.4
43.0
61.5
66.0
40.5
38.2
11.8
8.4
5.0
0.4
5.9
Mean 74.0
SD -r 6.9
84.1
85.0
72.0
95.6
78.4
97.7
82.2
Mean 85.0
SD 4 9.1
51.3
51.9
70.3
60.7
42.6
62.4
53.3
46.9
56.5
Mean 55.1
SD -- 8.4
62.3
70.7
67.5
56.2
Mean 64.2
SD 6.3
78.8
82.5
78.2
71.8
68.6
Mean 76.0
SD 4 5.6
* Previously studied while thyrotoxic.
Toxic
nodular
goiter
Graves'
disease,
toxic
Graves'
disease,
euthyroid
Graves'
disease,
myxedema
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TABLE ii-( Continued)
Thyroidal Acute thyroxine
24 hr I131 disappearance rate
Group Subject Age Sex Race PBI uptake Half-time
yrs lg% min
Spontaneous E.M. 71 F Cau. 1.3 157.6
primary G.E. 75 F Cau. 3.0 2.4 106.4
myxedema H.B. 69 F Cau. 0.6 1.2 106.4
C.D. 68 F Cau. 0.5 3.2 107.5
O.S. 59 M Cau. 1.0 86.5
M.B. 55 F N. 0.4 1.4 97.1
S.C. 85 F Cau. 0.2 4.3 111.5
Mean 110.4
SD 4 22.4
Liver disease J.H.t 24 M Cau. 7.8 111.9
L.T. 43 M Cau. 4.3 127.6
R.L. 42 M Cau. 6.4 250.9
O.T. 42 M Cau. 273.7
A.W. 46 F N. 5.6 135.0
F.T. 48 M Cau. 3.3 116.7
M.W. 67 M Cau. 5.6 15.4 111.5
J.E. 44 M Cau. 95.9
M.B. 44 F N. 248.8
Mean 163.6
SD 4 71.8
Normals W.S. 36 M N. 9.8 71.7
fed R.Q. 25 M Cau. 7.0 59.0
thyroid C.A. 29 M N. 10.0 62.4
G.K. 42 M Cau. 9.7 83.8
Mean 69.2
SD :1 11.1
t Studied during acute phase of infectious hepatitis.
the effects of thyroxine disposal from the body as
a whole should be negligible.1
Statistical analysis indicated the probability
that the portion of the curve for the relatively
short 20 to 50 minute interval was linear in each
case (p < 0.01). This linear portion of the re-
gression curve was solved mathematically in each
instance by the method of least squares and the
slope was determined (log y = a + bx). The
time required for the net counts per minute to de-
cline to one-half the intercept value at time zero
(time of injection of T4*) was obtained by ex-
trapolation and is expressed as the "acute thy-
1 Our data, which does not contain simultaneously de-
termined concentrations of extravascular T4*, does not per-
mit the calculation of a precise rate constant for transfer
of T4 out of plasma, either in normals or in the different
disorders studied. This would also require knowledge
of the rate constant for transfer of T4 from the ex-
travascular compartment to plasma. Thus, our results
are expressed merely as a "rate," rather than a rate con-
stant, and the slopes can not be considered to be true
zero-time slopes.
roxine disappearance half-time." The statistical
methods used were those described by Snedecor
(4).
Replicate studies. To determine reproducibility
in the same subject, ten subjects were restudied
after 2 to 4 days without treatment. Subjects were
selected on the basis of the first study to include
the range of values noted within the study groups.
Table I compares the results of first and second
studies. The mean of the difference (first study
minus second study) was - 3.6 minutes. Group
means for first and second studies were not sta-
tistically different (p > 0.50).
Euthyroid controls. The acute thyroxine disap-
pearance rate for 15 euthyroid controls was 74.0
minutes. Analysis of covariance indicated the like-
lihood of a common population regression coeffi-
cient for these subjects. Variations correlated
with age, sex or race could not be detected in this
relatively small group. Individual data for sub-
jects in this and subsequent groups are given in
Table II and in Figure 2.
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Liver disease. Marked prolongation of thyrox-
ine disappearance rate was noted in the eight pa-
tients with Laennec's cirrhosis and in the one with
acute infectious hepatitis. Details as to degree of
hepatic involvement are given in Table III. The
mean half-time of disappearance was 163.6 min-
utes. The slowest disappearance rates were ob-
served in the subjects with ascites, indicating that
expansion of the extracellular fluid volume need
not accelerate disappearance rate (as might be ex-
pected if this measured simple diffusion from the
intravascular compartment). The wide range of
values observed undoubtedly reflects different de-
grees of hepatic impairment, but could not be cor-
related with any of the recorded indices of liver
function. Difference from the control group was
highly significant (p < 0.001).
Hyperthyroidism. A sharp distinction between
patients with nodular toxic goiter and those with
diffuse toxic goiter (Graves' disease) was evident.
The mean half-time of thyroxine disappearance for
seven subjects with toxic nodular goiter (85.0
minutes) was actually significantly longer than
that observed in the controls (p < 0.01). By
contrast, nine patients with diffuse toxic goiter
had a mean thyroxine disappearance half-time of
55.1 minutes, very significantly shorter than the
control group (p < 0.001).
In an effort to clarify this difference four
healthy, euthyroid subjects were given increasing
amounts of desiccated thyroid over a 6-week pe-
riod, up to 20 grains daily. The thyroxine disap-
pearance rate was determined at 2-week intervals.
The results are summarized in Table II. As
noted by others (5-7), the subjects tolerated large
doses of thyroid well, although they manifested
weight loss, slight tremor, increased sweating and
mild tachycardia. The highest PBI value pro-
duced was 10.3 ,tg per 100 ml. Mean thyroxine
disappearance rate at the end of the experimental
period (after 20 grains of desiccated thyroid had
been administered daily for 1 week) was 69.2
minutes. This was not significantly different from
the euthyroid control group (p > 0.40) or from
the results in the same subjects before treatment
with desiccated thyroid. None of the subjects had
changes in disappearance rate falling outside the
95 per cent confidence limits for replicate studies
in untreated subjects.
Myxederna and treated hyperthyroidism. Mean
half-time of acute thyroxine disappearance for
seven subjects with spontaneous, primary myx-
edema was 110.4 minutes, a highly significant dif-
ference from the control group (p < 0.001).
When five subjects with Graves' disease were
studied after they had become profoundly myx-
edematous from treatment, their thyroxine disap-
pearance rate (mean half-time of 76.0 minutes)
was very significantly longer (p < 0.001) than in
hyperthyroid subjects with Graves' disease (mean
half-time of 55.1 minutes), but not significantly
different from that of euthyroid controls. Yet,
interestingly, the disappearance half-time of 76.0
minutes was significantly shorter than in those
with spontaneous myxedema (mean 110.4 min-
utes). Thus, although the development of myx-
TABLE III
Indices of hepatic function in subjects with liver disease
Acute
thyroxine
BSP Pro- disap-
reten- throm- pearance
tion at bin rate
45 min Serum time Choles- Half-
Subject Age Sex Race Ascites albumin Hgb. terol PBI time
yrs 7C g% sec g mg% 'Ug% min
L.T. 43 M Cau. + 40.6 1.91 12.7 9.5 140 4.3 127.6
A.W. 46 F N. 0 34.8 1.84 16.4 8.5 348 5.6 135.0
J.E. 44 M Cau. 0 31.4 3.15 19.0 10.0 100 95.9
J.H.* 24 M Cau. 0 t 3.90 13.4 14.0 215 7.8 111.9
O.T. 42 M Cau. + 42.8 3.60 13.4 7.0 308 273.7
M.W. 67 M Cau. 0 41.0 2.42 15.6 9.0 130 2.6 111.5
F.T. 48 M Cau. 0 12.4 15.0 3.3 116.7
R.L. 42 M Cau. + t 2.30 24.6 10.5 133 6.4 250.9
M.B. 44 F Catu. + t 2.20 28.5 9.0 138 248.8
* Acute infectious hepatitis,
t Icteric,
toot
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edema slows the disappearance rate, a specific dif-
ference in handling of labeled thyroxine seems to
exist in Graves' disease even when functional thy-
roid tissue is absent, or virtually so.
Euthyroid Graves' disease. Four subjects with
Graves' disease were studied when they were eu-
thyroid after treatment. One of these (V.H.) 'was
maintained on 3 grains of desiccated thyroid daily
because of moderately severe exophthalmos (the
elevated PBI noted in this case was attributed to
extraneous iodine ingestion). Subjects had been
euthyroid for from 3 months to 2 years. The
group mean was 64.2 minutes and differed from
the control group at marginal significance level
(p < 0.05).
DISCUSSION
The early phases of disappearance of intrave-
nously injected T4* from the circulation have not
been studied in detail. Limited data from other
sources (3, 8) and observations during the course
of the present studies implicate a complex series
of physiological events, many of which proceed
simultaneously. These events include: a) mixing
of T4* within the intravascular compartment with
almost immediate binding to the plasma proteins;
b) distribution throughout the extrathyroidal thy-
roxine pool with intravascular-extravascular com-
petition for T4*; c) specific trapping of thyroxine
by certain organs, particularly the liver; d) dis-
posal of T4* from the body via the gastrointestinal
tract, by excretion of small amounts in the urine
(8) and by metabolic degradation with subse-
quent appearance of free 1131 in the blood, the thy-
roid and the urine. In the present studies, cover-
ing only a 30-minute period, it is unlikely that deg-
radation of T4* is significant since the total turn-
over of endogenous thyroxine does not appear to
exceed 30 per cent per day even in hyperthyroid
states (9). The present studies are believed to
reflect primarily the events of b and c above,
namely, the early distribution and specific trapping
of thyroxine.
The half-time value determined from decreas-
ing blood levels of radioactivity in each case re-
flects the rate at which equilibrium between la-
beled and stable thyroxine is being approached
within the body. This process of equilibration is
occurring at different rates between the intra-
vascular and the many extravascular compart-
ments of the body. The method of measurement
employed in the present studies fails to distinguish
between these various rates, but reflects them col-
lectively. The technique intends only to estimate
the balance existing between forces regulating the
rate of removal of T4* from the circulation. Al-
though the calculated value does not represent a
true rate constant, the results obtained were re-
producible among groups of euthyroid individuals
and among individuals with the various patho-
logical states noted, and the results were statisti-
cally different between certain groups.
Factors which influence the acute rate of dis-
appearance of a tracer amount of T4* from the
blood include: a) the relative size of intra- and
extravascular thyroxine pools (e.g., a large in-
travascular pool of thyroxine would slow the rate
of disappearance); b) the relative thyroxine-
binding affinity and saturation of intra- and ex-
travascular proteins (e.g., increased intravascular
thyroxine-binding capacity would be associated
with a slower rate of removal of T4*); c) the in-
tegrity of the vascular lining which prevents ex-
travasation of protein-bound T4*; and d) the
ability of certain organs specifically to concentrate
protein-bound or free T4*.
The relationship of intravascular protein binding
of thyroxine to thyroidal economy in normal as
well as in pathological states has received consid-
erable attention. In vitro measurements of thy-
roxine-binding capacity permit comparison of the
binding affinity of plasma proteins in normal and
abnormal states under the conditions imposed by
the technique of measurement. The effectiveness
with which plasma proteins retain thyroxine within
the circulation of intact subjects, however, must
be equally dependent upon the relative binding
affinity of extravascular proteins as well as upon
the other factors mentioned above. The present
studies suggest a reasonably good correlation be-
tween the rate of removal of thyroxine from the
blood and in vitro estimates of plasma-binding ca-
pacity. In circumstances reported to exhibit in-
creased thyroxine-binding capacity of the serum
proteins, a delay in the acute disappearance of
thyroxine from the circulation was observed, i.e.,
in seven patients with primary myxedema, in a
single subject with acute hepatitis, and in sub-
jects given diethylstilbestrol (unpublished ob-
servations).
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The findings in subjects with various types of
hyperthyroidism are of particular interest. Sub-
jects with Graves' disease, at all levels of thyroid
function, had more rapid thyroxine disappearance
rates than other subjects with comparable levels
of metabolic activity. While it is clear, in com-
paring hyperthyroid, euthyroid, and hypothyroid
subjects with Graves' disease, that hyperthyroid-
ism has some influence on the function measured,
the failure to find significant similar acceleration
in subjects with toxic nodular goiter or in thyro-
toxicosis medicamentosa suggests a more specific
abnormality in Graves' disease. It may be argued
that subjects with Graves' disease simply have a
larger extravascular pool of thyroxine or that
there was greater saturation of binding proteins
(since PBI levels were somewhat higher in the
Graves' group). However, the persistence of ac-
celerated disappearance rate, in relation to others
with comparable metabolic status, in Graves' sub-
jects made hypothyroid, and probably also in
those made euthyroid, invalidates this argument.
Also, it is likely that those individuals with toxic
nodular goiter and thyrotoxicosis medicamentosa
had ample time to expand their extravascular thy-
roxine pools to a degree comparable to hyperthy-
roid Graves' subjects.
The data support the concept of a qualitative,
biological difference between Graves' disease and
toxic nodular goiter and suggest altered in vivo
plasma or possibly even tissue protein binding of
thyroxine in Graves' disease. Indeed, the abnor-
mality is apparent when these patients have be-
come myxedematous after treatment. In a pre-
liminary report, Richards, Dowling and Ingbar
(10) noted that thyroxine-binding by prealbumin
is usually decreased in untreated thyrotoxic pa-
tients with Graves' disease, but a similar defect in
subjects ill with other diseases was also observed.
It may be that defective prealbumin binding of
plasma in Graves' disease plays a significant role
in the phenomena observed in the acute thyroxine
disappearance rate. Our data and those of others
do not exclude the possible importance of extra-
vascular forces. Since we have not observed the
acute thyroxine disappearance rate to be accele-
rated in illnesses other than Graves' disease, the
defective prealbumin binding associated with some
nonspecific illnesses may in turn be balanced by a
comparable decrease in extravascular thyroxine-
binding capacity. Certainly, patients with non-
specific illnesses do not exhibit signs of hyper-
thyroidism.
Our observations on acute thyroxine disap-
pearance rate in Graves' disease are consonant
with the increased thyroxine turnover rates in
subjects with treated Graves' disease (11) and
with the finding that heterologous serum labeled
with T4* disappears from the circulation in ac-
cordance with the recipient's thyroid status rather
than the donor's (12). Also, Hamolsky, Ellison
and Freedberg have shown that labeled thyroxine
is more avidly incorporated by guinea pig dia-
phragm in vitro from sera of patients with Graves'
disease than from sera of subjects with toxic
nodular goiter or sera from normals enriched in
vitro to hyperthyroid levels of PBI (13). By
contrast, they found that labeled thyroxine mixed
with sera from subjects with Graves' disease disap-
peared more rapidly from the circulation of re-
cipient dogs than when mixed with sera from
normals or subjects with toxic nodular goiter.
This finding is not easily interpreted without
knowledge of the relative binding affinity for thy-
roxine of dog and human serum or of dog's ex-
travascular proteins. Their findings may reflect
poorer thyroxine binding by Graves' plasma and
represent distributional phenomena rather than
peripheral metabolic factors.
The finding of an actual, although slight, pro-
longation of thyroxine disappearance rate in sub-
jects with toxic nodular goiter may be due to ex-
pansion of intravascular pool size out of propor-
tion to increase in turnover. It is equally pos-
sible that this prolongation is related to the in-
creased age (although other older patients did not
share this finding) or to minor impairment of he-
patic function (clinically not apparent).
The acute thyroxine disappearance rate was
consistently and markedly prolonged in subjects
with cirrhosis of the liver; in most instances the
disappearance rates were even longer than in pa-
tients with spontaneous myxedema. While in-
creased binding of thyroxine by plasma globulins
has been described in hepatitis where the PBI is
often elevated (14), this seems unlikely in Laen-
nec's cirrhosis. In the latter, the PBI is usually
normal or even low, and increased red cell uptake
of triiodothyronine in vitro has been reported
(15). The latter finding has been attributed to
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decreased binding affinity by the serum proteins
in this condition. If such is the case in most in-
stances of cirrhosis, it would then seem that in-
travascular factors (e.g., the ability of the plasma
proteins to bind thyroxine) are of much less im-
portance than are extravascular phenomena in
effecting the acute thyroxine disappearance rate
in liver disease. Thus, the liver may play a more
important role in the handling and metabolism of
thyroxine than has generally been appreciated.
Preliminary observations during these studies and
observations by others (8) indicate that thyroxine
rapidly accumulates in the liver. Since fecal ex-
cretion of organic iodine is small (9, 16), this
must indicate that: a) thyroxine trapped by the
liver is excreted in the bile and reabsorbed via the
enterohepatic circulation; b) thyroxine is released
to the circulation after hepatic trapping, free or in
bound form; or c) the liver stores large amounts
of thyroxine for its own metabolic needs. Quan-
titative data are not available to decide which of
the possibilities might predominate in affecting the
acute handling of thyroxine.
The results of the present studies are very simi-
lar to those recently reported by Peterson and
Pierce (17) regarding the disappearance of cor-
tisol, cortisone and corticosterone from the in-
travascular space. Alterations from normal in
the rates of disappearance of these steroids were
noted in cirrhosis, myxedema, thyrotoxicosis 2 and
after administration of estrogen to normal sub-
jects. These qualitative changes were similar to
those we have reported for I131-thyroxine.
SUMMARY AND CONCLUSIONS
1. A method is described for the determination
of the rate at which equilibrium between intra-
and extravascular thyroxine pools is approached
after intravenous administration of labeled thy-
roxine. This measurement, termed the "acute
thyroxine disappearance rate" is accomplished
during a 30-minute period beginning 20 minutes
after the intravenous injection of I131-labeled
L-thyroxine.
2. Subjects with Graves' disease were found to
have shorter acute thyroxine disappearance rates
2 By personal communication, we are informed that
all of their patients with "thyrotoxicosis" suffered from
Graves' disease.
at all levels of thyroid function than other sub-
jects with comparable thyroidal activity. Even
when functionally athyrotic, the patients with
treated Graves' disease handled thyroxine differ-
ently from athyrotic subjects without Graves'
disease. This observation suggests that plasma or
extravascular protein binding of thyroxine in sub-
jects with Graves' disease may be altered in vivo
and that this alteration is not the direct result of
hypermetabolism or hyperthyroidism.
3. No significant shortening of thyroxine disap-
pearance rate was noted in patients with toxic
nodular goiter or in normals fed exogenous thy-
roid. This finding indicates a qualitative differ-
ence between the toxic nodular goiter and Graves'
disease. These observations cannot be accounted
for by differences in the level of the PBI or deriva-
tives of this measurement, since the thyroxine
disappearance rate in Graves' disease remained
relatively rapid after treatment of hyperthyroidism.
4. Greatly prolonged thyroxine disappearance
rates in subjects with liver disease suggest that the
liver plays an important role in the handling of
thyroxine.
5. Replicate experiments indicate that the method
of study is reproducible and applicable to the study
of drug and hormone effects on the rate of egress
of labeled hormone from the circulation.
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